Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia (AA) a Bayesian Optimal Phase II study

Trial Profile

Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia (AA) a Bayesian Optimal Phase II study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avatrombopag (Primary)
  • Indications Aplastic anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DIAAMOND-Ava FIRST
  • Most Recent Events

    • 13 Dec 2022 Results (n=40) assessing safety and efficacy of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naive and Relapsed/Refractory Severe Aplastic Anaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 13 Nov 2019 Status changed from not yet recruiting to recruiting.
    • 24 Jul 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top